Ultragenyx Pharma (RARE) Misses Q2 EPS by 45c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Ultragenyx Pharma (RARE) Misses Q2 EPS by 45c, Revenues Beat

Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update

August 2, 2021 4:05 PM EDT

Second quarter 2021 total revenue of $87.0 million including Crysvita1 revenue to Ultragenyx of $44.7 million

2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million reaffirmed

Strong Dojolvi launch continues with approximately 220 patients on reimbursed commercial therapy in the United States

Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome to begin enrolling patients in Canada and the U.K.; U.S. pending protocol revisions

NOVATO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:... More